PATENTS AND PROPRIETARY TECHNOLOGY
We seek to protect our technology through the use of patents, trademarks and trade secrets. We are the owner or licensee of 136 issued United States (U.S.) patents, and corresponding foreign patents, relating to our structural heart repair implant technologies and other related cardiovascular implant technologies. In addition, we have more than 69 pending U.S. patent applications in the field of structural heart repair, including implants, delivery systems and accessory products, some of which have corresponding foreign counterparts.
The issued U.S. patents expire at various dates ranging from 2010 to 2026. The patents related to our anastomosis devices, which are minimally invasive means of attaching vascular grafts, expire in 2016, the patent for our radiopaque markers, which allow catheters to be more visible under x-ray, expires in 2014, the patents for our distal protection system expire from 2019 to 2022, the patent for our nitinol septal repair device expires in
Market Data 
Markets 
AI
